NCT01072812View on ClinicalTrials.gov

Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Alzheimer's DiseaseAmnestic Mild Cognitive Impairment
Interventions
DRUG

Posiphen® tartrate capsules

Capsules administered (240 mg/day) for 10 days Capsules administered (160 mg/day) for 10 days

Trial Locations (1)

78217

CEDRA Clinical Research, LLC, San Antonio

Sponsors

Lead Sponsor

Annovis Bio Inc.
All Listed Sponsors
lead

Annovis Bio Inc.

INDUSTRY